Helius Medical Technologies Stock Forecast, Price & News

+0.03 (+0.20 %)
(As of 07/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume369 shs
Average Volume75,517 shs
Market Capitalization$35.47 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HSDT News and Ratings via Email

Sign-up to receive the latest news and ratings for Helius Medical Technologies and its competitors with MarketBeat's FREE daily newsletter.

Helius Medical Technologies logo

About Helius Medical Technologies

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.55 out of 5 stars

Medical Sector

864th out of 2,218 stocks

Electromedical Equipment Industry

21st out of 65 stocks

Analyst Opinion: 3.3Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Helius Medical Technologies (NASDAQ:HSDT) Frequently Asked Questions

Is Helius Medical Technologies a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Helius Medical Technologies in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Helius Medical Technologies stock.
View analyst ratings for Helius Medical Technologies
or view top-rated stocks.

What stocks does MarketBeat like better than Helius Medical Technologies?

Wall Street analysts have given Helius Medical Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Helius Medical Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Helius Medical Technologies' next earnings date?

Helius Medical Technologies is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Helius Medical Technologies

How were Helius Medical Technologies' earnings last quarter?

Helius Medical Technologies, Inc. (NASDAQ:HSDT) posted its earnings results on Monday, May, 17th. The company reported ($1.65) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.51) by $0.14. The company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.09 million. Helius Medical Technologies had a negative trailing twelve-month return on equity of 200.84% and a negative net margin of 2,362.52%.
View Helius Medical Technologies' earnings history

How has Helius Medical Technologies' stock price been impacted by Coronavirus (COVID-19)?

Helius Medical Technologies' stock was trading at $18.9035 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HSDT shares have decreased by 19.0% and is now trading at $15.31.
View which stocks have been most impacted by COVID-19

When did Helius Medical Technologies' stock split? How did Helius Medical Technologies' stock split work?

Shares of Helius Medical Technologies reverse split before market open on Thursday, December 31st 2020. The 1-35 reverse split was announced on Thursday, December 31st 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 4th 2021. An investor that had 100 shares of Helius Medical Technologies stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for HSDT?

3 analysts have issued twelve-month price targets for Helius Medical Technologies' shares. Their forecasts range from $20.00 to $20.00. On average, they expect Helius Medical Technologies' share price to reach $20.00 in the next year. This suggests a possible upside of 30.6% from the stock's current price.
View analysts' price targets for Helius Medical Technologies
or view top-rated stocks among Wall Street analysts.

Who are Helius Medical Technologies' key executives?

Helius Medical Technologies' management team includes the following people:
  • Dane Carl Andreeff, President, Chief Executive Officer & Director
  • Joyce N. LaViscount, Chief Operating Officer & Secretary
  • Jeffrey S. Mathiesen, Chief Financial Officer & Treasurer
  • Antonella Favit-Van Pelt, Chief Medical Officer
  • Frederick Fantazzia, VP-Sales & Marketing North America Region

Who are some of Helius Medical Technologies' key competitors?

What is Helius Medical Technologies' stock symbol?

Helius Medical Technologies trades on the NASDAQ under the ticker symbol "HSDT."

How do I buy shares of Helius Medical Technologies?

Shares of HSDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Helius Medical Technologies' stock price today?

One share of HSDT stock can currently be purchased for approximately $15.31.

How much money does Helius Medical Technologies make?

Helius Medical Technologies has a market capitalization of $35.47 million and generates $660,000.00 in revenue each year. The company earns $-14,130,000.00 in net income (profit) each year or ($11.80) on an earnings per share basis.

How many employees does Helius Medical Technologies have?

Helius Medical Technologies employs 19 workers across the globe.

What is Helius Medical Technologies' official website?

The official website for Helius Medical Technologies is

Where are Helius Medical Technologies' headquarters?

Helius Medical Technologies is headquartered at 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940.

How can I contact Helius Medical Technologies?

Helius Medical Technologies' mailing address is 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940. The company can be reached via phone at (215) 944-6100 or via email at [email protected]

This page was last updated on 7/28/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.